Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors (NCT06726148)
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Phase I: Characterize safety and tolerability of ECI830 as a single agent and in combination with ribociclib and fulvestrant. Identify dose range for optimization/recommended dose for future studies. Phase II: Assess the anti-tumor activity of ECI830 in combination with ribociclib and fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer.
Who can join: Review the eligibility criteria below.
Location: University of California LA — Los Angeles, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (33 Sites)
Showing the first 25 of 33 sites.
- University of California LA — Los Angeles, California
- Florida Cancer Specialists — Fort Myers, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- WA Uni School Of Med — St Louis, Missouri
- Memorial Sloan Kettering — New York, New York
- SCRI Oncology Partners — Nashville, Tennessee
- MD Anderson Cancer Center Uni of Te — Houston, Texas
- Fred Hutch Cancer Research — Seattle, Washington
- Novartis Investigative Site — Clayton, Victoria
- Novartis Investigative Site — Melbourne, Victoria
- Novartis Investigative Site — Toronto, Ontario
- Novartis Investigative Site — Montreal, Quebec
- Novartis Investigative Site — Nanjing, Jiangsu
- Novartis Investigative Site — Xian, Shanxi
- Novartis Investigative Site — Brno,
- Novartis Investigative Site — Copenhagen,
- Novartis Investigative Site — Odense C,
- Novartis Investigative Site — Bordeaux,
- Novartis Investigative Site — Saint-Herblain,
- Novartis Investigative Site — Freiburg im Breisgau, Baden-Wurttemberg
- Novartis Investigative Site — Heidelberg,
- Novartis Investigative Site — Ulm,
- Novartis Investigative Site — Haifa,
- Novartis Investigative Site — Tel Aviv,
- Novartis Investigative Site — Milan, MI
📞 Contact the Study Coordinator
Phone: (888) 669-6682
Email: novartis.email@novartis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced HR+/HER2- Breast Cancer
Explore by condition: All Advanced HR+/HER2- Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.